10. (Amended) A composition comprising a polypeptide according to claim 1 in association with a carrier or diluent.

11. (Amended) A method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with a polypeptide according to claim 1 under conditions to provide for apoptosis.

13. (Amended) A polypeptide according to claim 1 for use in a method of treatment of the human or animal body.

REMARKS

The above amendments are made to eliminate improper multiple dependencies according to U.S. practice.

An early and favorable Action on the merits is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

B. J. Sadoff
Reg. No. 36,663

BJS:ms
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

8. (Amended) A polypeptide according to [any one of the preceding claims] claim 1 which inhibits the binding of an E2F protein to an E2F DNA binding site with an *in vitro* IC50 of less than 100μM.

9. (Amended) A polypeptide which comprises a first portion having the amino acid sequence of a polypeptide defined in [any one of claims 1 to 8] claim 1 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

10. (Amended) A composition comprising a polypeptide according to [any one of the preceding claims] claim 1 in association with a carrier or diluent.

11. (Amended) A method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with a polypeptide according to [any one of claims 1 to 9, or a composition according to claim 10,] claim 1 under conditions to provide for apoptosis.

13. (Amended) A polypeptide according to claim 1 [any one of claims 1 to 9 or a composition according to claim 10] for use in a method of treatment of the human or animal body.